Success Metrics

Clinical Success Rate
72.7%

Based on 8 completed trials

Completion Rate
73%(8/11)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_2
4
36%
Ph phase_1
7
64%

Phase Distribution

7

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 2Efficacy & side effects
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(3)

Detailed Status

Completed8
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
72.7%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (63.6%)
Phase 24 (36.4%)

Trials by Status

terminated327%
completed873%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

Renal Allograft Tolerance Through Mixed Chimerism

NCT01780454
terminatedphase_2

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

NCT00113646
completedphase_2

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
completedphase_1

Study of MEDI 507 in the Treatment of Pediatric Patients

NCT00813618
completedphase_1

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00807794
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01780454Phase 1

Renal Allograft Tolerance Through Mixed Chimerism

Completed
NCT00113646Phase 2

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Terminated
NCT00801632Phase 2

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

Completed
NCT00813618Phase 1

Study of MEDI 507 in the Treatment of Pediatric Patients

Completed
NCT00807794Phase 1

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Completed
NCT00806728Phase 1

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Completed
NCT00806208Phase 1

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Completed
NCT00540618Phase 2

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

Completed
NCT00123942Phase 1

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Terminated
NCT00105313Phase 1

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Terminated
NCT00192452Phase 2

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11